EICHORPublic-registry site landscape for NCT07752810, “Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout”, a Gout study sponsored by Hangzhou Grand Biologic Pharmaceutical, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07752810 (registry record) |
| Study title | Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout |
| Official title | A Multicenter, Open-Label, Dose-Escalation and Expansion Phase Ib/II Study to Evaluate the Safety, PK, and PD of Multiple Ascending Doses of HZBio1 in Patients With Gout |
| Sponsor | Hangzhou Grand Biologic Pharmaceutical, Inc. |
| Condition(s) | Gout |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 1 |
| Intervention(s) | Phase 1b: HZBio1 3mg, Phase 1b: HZBio1 6mg, Phase 1b: HZBio1 12mg, Phase 2: HZBio1 6mg, Phase 2: HZBio1 9mg, Phase 2: HZBio1 12mg |
| Site countries | China |
At Huashan Hospital, Fudan University — one of the facilities listed on this trial — 4 other studies are actively recruiting Gout patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07752810.
Eichor generates a preliminary site-risk snapshot for NCT07752810 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
